1
|
Mutin J, Orhon P, Choisnard L, Lassiaz M, Bacot S, Ahmadi M, De Leiris N, Djaileb L, Broisat A, Ghezzi C, Bedouch P, Brunet MD, Leenhardt J. Validation of HPLC and TLC analytical methods to determine radiochemical purity of 99mTc-cAbVCAM1-5, a new experimental radiotracer. J Pharm Biomed Anal 2024; 246:116224. [PMID: 38759321 DOI: 10.1016/j.jpba.2024.116224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 05/07/2024] [Accepted: 05/13/2024] [Indexed: 05/19/2024]
Abstract
Cardiovascular diseases, including fatal myocardial infarctions from atheromatous plaques, are the primary global mortality cause. Detecting stenotic atheromatous plaques is possible through coronary angiography, but vulnerable plaques with eccentric remodeling are undetectable with current diagnostic methods. Addressing this challenge, our group developed a radiopharmaceutical drug targeting vascular cell adhesion molecule 1 (VCAM-1), radiolabeled with technetium-99m. Given the absence of a monograph in the European Pharmacopoeia, and in order to draft the investigational medicinal product documentation, analytical methods had to be validated by high performance liquid chromatography (HPLC) and thin layer chromatography (TLC) to determine the radiochemical purity (RCP) of 99mTc-cAbVCAM1-5. This study therefore presents the results of the validation of analytical methods obtained in this context. The method validation followed the European Association of Nuclear Medicine (EANM) recommendations adapted from ICH Q2(R1), ensuring conformity with specificity, accuracy, repeatability and intermediate precision, linearity, robustness, quantification limit (LoQ), and range criteria. Regarding the results of specificity, both HPLC and TLC methods demonstrated excellent separation of 99mTc-cAbVCAM1-5 from impurities 99mTcO4-. Accuracy results indicated recovery percentages within the range of 99.52-101.40% for the HPLC and 99.51-101.97% for TLC, ensuring reliable measurements for each concentration of 99mTcO4-. Precision of the methods was validated by assessing repeatability and intermediate precision. Linearity was determined over the usual concentrations range and the correlation coefficient was greater than 0.99 for both methods. The limit of quantification was measured by diluting the 99mTcO4- to obtain a signal-to-noise ratio of around 10:1. Under these conditions, we obtained an LOQ of 2.10 MBq/mL for HPLC and 2Mbq/mL for TLC. In conclusion, the analytical methods developed in this study comply with EANM recommendations. This therefore allows us to correctly assess the radiochemical purity of 99mTc-cAbVCAM1-5, a new radiotracer targeting inflammation in vulnerable plaques.
Collapse
Affiliation(s)
- Juliette Mutin
- Univ. Grenoble Alpes, Pharmacy Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, Nuclear Medicine Department, CHU Grenoble Alpes, Grenoble 38000, France
| | - Pauline Orhon
- Univ. Grenoble Alpes, Pharmacy Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, Nuclear Medicine Department, CHU Grenoble Alpes, Grenoble 38000, France
| | - Luc Choisnard
- Univ. Grenoble Alpes, CNRS, DPM, UMR 5063, Grenoble 38000, France
| | - Maxime Lassiaz
- Univ. Grenoble Alpes, Pharmacy Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, Nuclear Medicine Department, CHU Grenoble Alpes, Grenoble 38000, France
| | - Sandrine Bacot
- Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France
| | - Mitra Ahmadi
- Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France
| | - Nicolas De Leiris
- Univ. Grenoble Alpes, Nuclear Medicine Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France
| | - Loic Djaileb
- Univ. Grenoble Alpes, Nuclear Medicine Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France
| | - Alexis Broisat
- Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France
| | - Catherine Ghezzi
- Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France
| | - Pierrick Bedouch
- Univ. Grenoble Alpes, Pharmacy Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, CNRS TIMC-IMAG, UMR 5525, Grenoble 38000, France
| | - Marie-Dominique Brunet
- Univ. Grenoble Alpes, Pharmacy Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, Nuclear Medicine Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France
| | - Julien Leenhardt
- Univ. Grenoble Alpes, Pharmacy Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, Nuclear Medicine Department, CHU Grenoble Alpes, Grenoble 38000, France; Univ. Grenoble Alpes, INSERM, LRB, UMR 1039, Grenoble 38000, France.
| |
Collapse
|
2
|
Migliari S, Scarlattei M, Baldari G, Ruffini L. Scale down and optimized automated production of [68Ga]68Ga-DOTA-ECL1i PET tracer targeting CCR2 expression. EJNMMI Radiopharm Chem 2023; 8:3. [PMID: 36729317 PMCID: PMC9895323 DOI: 10.1186/s41181-023-00188-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 01/13/2023] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Recently it has been identified a short peptide that showed allosteric antagonism against C-C motif chemokine receptor 2 (CCR2) expressed on inflammatory monocyte and macrophages. A 7-D-amino acid peptidic CCR2 inhibitor called extracellular loop 1 inverso (ECL1i), d(LGTFLKC) has been identified and labeled to obtain a new probe for positron emission tomography in pulmonary fibrosis, heart injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer. Our goal was to develop, optimize and validate an automated synthesis method for [68Ga]68Ga-DOTA-ECL1i to make it available for a broader community. The synthesis of [68Ga]68Ga-DOTA-ECL1i was done using the Scintomics GRP® module with the already estabilished synthesis template for [68Ga]68Ga-DOTATOC/[68Ga]68Ga-PSMA. The radiopharmaceutical production was optimized scaling down the amount of DOTA-ECL1i (from 50 to 10 μg), evaluating synthesis efficiency and relevant quality control parameters in accordance with the European Pharmacopeia. RESULTS Best results were yielded with 20 μg DOTA-ECL1i and then the process validation was carried out by producing three different batches on three different days obtaining an optimal radiochemical yield (66.69%) as well as radiochemical purity (100%) and molar activity (45.41 GBq/µmol). CONCLUSIONS [68Ga]68Ga-DOTA-ECL1i was successfully synthesized and it is, thus, available for multi-dose application in clinical settings.
Collapse
Affiliation(s)
- Silvia Migliari
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Maura Scarlattei
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Giorgio Baldari
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Livia Ruffini
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| |
Collapse
|
3
|
Sammartano A, Migliari S, Serreli G, Scarlattei M, Baldari G, Ruffini L. Validation of the HPLC Analytical Method for the Determination of Chemical and Radiochemical Purity of Ga-68-DOTATATE. Indian J Nucl Med 2023; 38:1-7. [PMID: 37180199 PMCID: PMC10171759 DOI: 10.4103/ijnm.ijnm_11_22] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 03/18/2022] [Accepted: 04/04/2022] [Indexed: 02/25/2023] Open
Abstract
Purpose of the Study Ga-68-DOTA-peptides targeting somatostatin receptors have been assessed as a valuable tool in neuroendocrine tumors imaging using positron emission tomography (PET). A new selective and sensitive high-pressure liquid chromatography (HPLC) method was developed for determining chemical and radiochemical purity of Ga-68-DOTATATE (PET) tracer. The identification of peaks was achieved on a symmetry C18 column 3 μm 120Å (3.0 mm × 150 mm spherical particles) using (A) water + 0.1% trifluoroacetic acid (TFA) and (B) acetonitrile + 0.1% TFA, as the mobile phases at a flow rate of 0.600 mL/min and monitored at 220 nm. The run time was 16 min. Materials and Methods The method was validated to fulfill International Conference on Harmonization requirements and EDQM guidelines, and it included specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision. Results The calibration curve was linear over the concentration range from 0.5 to 3 μg/ml, with a correlation coefficient (r2) equal to 0.999, average coefficient of variation (CV%) 2%, and average bias% did not deviate more than 5% for all concentrations. The LOD and LOQ for DOTATATE were 0.5 and 0.1 μg/mL, respectively. The method was considered precise, obtaining coefficients of variation between 0.22% and 0.52% for intraday and 0.20% and 0.61% for interday precision. Accuracy of method was confirmed with average bias% that did not deviate more than 5% for all concentrations. Conclusion All results were acceptable and this confirmed that the method is suitable for its intended use in routine quality control of Ga-68-DOTATATE to guarantee the high quality of the finished product before release.
Collapse
Affiliation(s)
- Antonino Sammartano
- Department of Nuclear Medicine and Molecular Imaging, University Hospital of Parma, Via Gramsci, Italy
| | - Silvia Migliari
- Department of Nuclear Medicine and Molecular Imaging, University Hospital of Parma, Via Gramsci, Italy
| | - Giulio Serreli
- Department of Diagnostic, Medical Physics Unit, University Hospital of Parma, Via Gramsci, Parma, Italy
| | - Maura Scarlattei
- Department of Nuclear Medicine and Molecular Imaging, University Hospital of Parma, Via Gramsci, Italy
| | - Giorgio Baldari
- Department of Nuclear Medicine and Molecular Imaging, University Hospital of Parma, Via Gramsci, Italy
| | - Livia Ruffini
- Department of Nuclear Medicine and Molecular Imaging, University Hospital of Parma, Via Gramsci, Italy
| |
Collapse
|
4
|
Migliari S, Scarlattei M, Baldari G, Silva C, Ruffini L. A Specific HPLC Method to Determine Residual HEPES in [ 68Ga]Ga-Radiopharmaceuticals: Development and Validation. Molecules 2022; 27:molecules27144477. [PMID: 35889351 PMCID: PMC9323806 DOI: 10.3390/molecules27144477] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Revised: 07/05/2022] [Accepted: 07/07/2022] [Indexed: 01/25/2023] Open
Abstract
Background: Nowadays, in Nuclear Medicine, clinically applied radiopharmaceuticals must meet quality release criteria such as high radiochemical purity and radiochemical yield. Many radiopharmaceuticals do not have marketing authorization and have no dedicated monograph within European Pharmacopeia (Ph. Eur.); therefore, general monographs on quality controls (QCs) have to be applied for clinical application. These criteria require standardization and validation in labeling and preparation, including quality controls measurements, according to well defined standard operation procedures. However, QC measurements are often based on detection techniques that are specific to a certain chromatographic system. Several radiosyntheses of [68Ga]Ga-radiopharmaceuticals are more efficient and robust when they are performed with 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) buffer, which is considered as an impurity to be assessed in the QC procedure, prior to clinical use. Thus, Ph. Eur. has introduced a thin-layer chromatography (TLC) method to quantify the HEPES amount that is present in [68Ga]Ga-radiopharmaceuticals. However, this is only qualitative and has proven to be unreliable. Here we develop and validate a new high-performance liquid chromatography (UV-Radio-HPLC) method to quantify the residual amount of HEPES in 68Ga-based radiopharmaceuticals. Method: To validate the proposed UV-Radio-HPLC method, a stepwise approach was used, as defined in the guidance document that was adopted by the European Medicines Agency (CMP/ICH/381/95 2014). The assessed parameters are specificity, linearity, precision (repeatability), accuracy, and limit of quantification. A range of concentrations of HEPES (100, 80, 60, 40, 20, 10, 5, 3 μg/mL) were analyzed. Moreover, to test the validity and pertinence of our new HPLC method, we analyzed samples of [68Ga]Ga-DOTATOC; [68Ga]Ga-PSMA; [68Ga]Ga-DOTATATE; [68Ga]Ga-Pentixafor; and [68Ga]Ga-NODAGA-Exendin-4 from different batches that were prepared for clinical use. Results: In the assessed samples, HEPES could not be detected by the TLC method that was described in Ph. Eur. within 4 min incubation in an iodine-saturated chamber. Our developed HPLC method showed excellent linearity between 3 and 100 μg/mL for HEPES, with a correlation coefficient (R2) for calibration curves that was equal to 0.999, coefficients of variation (CV%) < 2%, and percent deviation value of bias from 100% to 5%, in accordance with acceptance criteria. The intra-day and inter-day precision of our method was statistically confirmed and the limit-of-quantification (LOQ) was 3 μg/mL, confirming the high sensitivity of the method. The amount of HEPES that was detected with our developed HPLC method in the tested [68Ga]Ga-radiopharmaceuticals resulted well below the Ph. Eur. limit, especially for [68Ga]Ga-NODAGA-Exendin-4. Conclusions: The TLC method that is described in Ph. Eur. to assess residual HEPES in [68Ga]-based radiopharmaceuticals may not be sufficiently sensitive and thus unsuitable for QC release. Our new HPLC method was sensitive, quantitative, reproducible, and rapid for QCs, allowing us to exactly determine the residual HEPES amount in [68Ga]Ga-radiopharmaceuticals for safe patient administration.
Collapse
Affiliation(s)
- Silvia Migliari
- Nuclear Medicine and Molecular Imaging Department, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy; (M.S.); (G.B.); (L.R.)
- Correspondence: ; Tel.: +39-3335939138
| | - Maura Scarlattei
- Nuclear Medicine and Molecular Imaging Department, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy; (M.S.); (G.B.); (L.R.)
| | - Giorgio Baldari
- Nuclear Medicine and Molecular Imaging Department, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy; (M.S.); (G.B.); (L.R.)
| | - Claudia Silva
- Food and Drug Sciences Department, Parco Area delle Scienze 27/A, University of Parma, 43124 Parma, Italy;
| | - Livia Ruffini
- Nuclear Medicine and Molecular Imaging Department, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy; (M.S.); (G.B.); (L.R.)
| |
Collapse
|
5
|
Sammartano A, Migliari S, Scarlattei M, Baldari G, Serreli G, Lazzara C, Garau L, Ghetti C, Ruffini L. Performance and long-term consistency of five Galliform 68Ge/68Ga generators used for clinical Ga-68 preparations over a 4 year period. Nucl Med Commun 2022; 43:568-576. [PMID: 35190517 DOI: 10.1097/mnm.0000000000001545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Gallium-68 is a positron emitter for PET applications that can be produced without cyclotron by a germanium (Ge-68) chloride/gallium (Ga-68) chloride generator. Short half-life (67.71 min) of Ga-68, matching pharmacokinetic properties of small biomolecules, facilitates isotope utilization in compounding radiopharmaceuticals for PET imaging. The increasing cost of good manufacturing practice-compliant generators has strengthened the need for radionuclide efficient use by planning specific radiopharmaceutical sessions during the week, careful maintenance of the generator and achievement of high labeling yield and radiochemical purity (RCP) of the radiolabeled molecules. METHODS The aim of this study was to evaluate the annual performance of five consecutive 68Ge/68Ga generators used for small-scale preparations of 68Ga-radiopharmaceuticals. To assess the long-term efficiency of isotope production we measured the weekly elution yield. To assess process efficiency we measured elution yield, labeling yield and RCP of four radiopharmaceutical preparations (68Ga-DOTATOC, 68Ga-PSMA-HBED-CC, 68Ga-PENTIXAFOR and 68Ga-DOTATATE). RESULTS The annual mean elution yield of the generators was 74.7%, higher than that indicated by the manufacturer, and it never went below 65%. The Ge-68 level in the final products was under the detection limits in all the produced batches (mean value 0.0000048%). The RCP of radiopharmaceuticals determined by high-performance liquid chromatography was 98 ± 0.22%. The mean yield of radiolabelling was 64.68, 68.71, 57 and 63.68% for 68Ga-DOTATOC, 68Ga-PSMA-HBED-CC, 68GaPENTIXAFOR and 68Ga-DOTATATE. CONCLUSION The ability to prepare in the hospital radiopharmacy high-purity and pharmaceutically acceptable 68Ga-radiolabeled probes on a routine basis facilitates patient access to precision imaging for clinical and research aims.
Collapse
Affiliation(s)
| | | | | | | | - Giulio Serreli
- Diagnostic Department, Medical Physics Unit, Azienda Ospedaliero-Universitaria di Parma, Gramsci, Parma, Italy
| | | | | | - Caterina Ghetti
- Diagnostic Department, Medical Physics Unit, Azienda Ospedaliero-Universitaria di Parma, Gramsci, Parma, Italy
| | | |
Collapse
|
6
|
Development and Validation of Analytical Methods for Radiochemical Purity of 177Lu-PSMA-1. Pharmaceuticals (Basel) 2022; 15:ph15050522. [PMID: 35631349 PMCID: PMC9143309 DOI: 10.3390/ph15050522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 04/21/2022] [Accepted: 04/22/2022] [Indexed: 01/26/2023] Open
Abstract
Prostate Specific Membrane Antigen (PSMA) is a highly relevant target in nuclear medicine due to its overexpression in prostate cancer. The 68Ga/177Lu-PSMA-1 combination is a theranostic agent for the detection and treatment of tumors overexpressing the PSMA target. Specifically, 177Lu-PSMA-1 is used in the treatment of castration-resistant prostate cancer that is ineffective or intolerant to the latest generation of chemotherapy and/or hormone therapy. This radiopharmaceutical is manufactured in a radiopharmaceutical synthesizing unit and must pass a quality control where the radiochemical purity (RCP) is assessed prior to release of the batch. RCP evaluation is performed by high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC). Since there is no monograph for 177Lu-PSMA-1 in the European Pharmacopoeia, we validate the analytical methods according to the EANM recommendations adapted from ICH Q2. Specificity, linearity, accuracy, precision, intermediate precision, limit of quantification (LOQ) and robustness were described for HPLC and TLC in this study. The results obtained demonstrated the robustness and reliability of the HPLC and TLC analytical methods for the evaluation of the RCP of 177Lu-PSMA-1.
Collapse
|